Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic

Ramey, Olivia L; Almodóvar, Armando Silva; Nahata, Milap C.

doi:10.1016/j.anai.2022.02.010

Cited by 20 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 31 Another study from England suggests that medication use declined during the first eight months of the pandemic. 32 Studies from the US have also suggested decreased adherence to controller medications amongst patients with asthma for both children 33 and adults 34 during the pandemic. Even if the observed reductions were due to improved self-management including high medication adherence during the pandemic, more plausible underlying factors are the various non-pharmacological interventions during the pandemic that led to reduced social interactions and the associated reduced risks of contracting viral infections.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database

Shah

Quint

Sheikh

2022

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database

Shah

Quint

Sheikh

2022

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

“…Previous research has highlighted a negative association between depressive symptoms and treatment adherence in older adults with asthma [ 15 , 16 ]. There have been substantial declines in medication adherence among older adults with asthma during the pandemic [ 17 ], emphasizing the importance of increasing healthcare accessibility so that clinicians can be attuned to both adherence behaviours and mental health symptoms among asthma patients.…”

Section: Discussionmentioning

confidence: 99%

Incident and recurrent depression among older adults with asthma during the COVID-19 pandemic: Findings from the Canadian Longitudinal Study on Aging

MacNeil

Jiang

et al. 2023

Respiratory Medicine

View full text Add to dashboard Cite

“…Clinical experience during the global pandemic and the ensuing restrictions in Arab countries, including in the Gulf, showed delayed outpatient follow-up, medication interruptions, and decreased access to non-emergency healthcare [38,39]. Changes in pharmacological adherence due to the COVID-19 pandemic have been documented in several studies worldwide, across a wide range of chronic diseases [40][41][42].…”

Section: Plos Onementioning

confidence: 99%

Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study

et al. 2023

View full text Add to dashboard Cite

Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. Methods ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months’ prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation. Results Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and/or hypertension. Baseline LDL-C levels (mean ± SD 3.6 ± 1.4 mmol/L in Saudi Arabia, 3.1 ± 1.4 mmol/L in Kuwait) were reduced by approximately 57%–62% in the first 6 months after evolocumab initiation (1.5 ± 1.2 mmol/L in Saudi Arabia [n = 63], 1.2 ± 0.8 mmol/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (<1.8 mmol/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (<1.4 mmol/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site. Conclusion Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations.

show abstract

Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic

Cited by 20 publications

References 24 publications

Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database

Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database

Incident and recurrent depression among older adults with asthma during the COVID-19 pandemic: Findings from the Canadian Longitudinal Study on Aging

Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study

Contact Info

Product

Resources

About